PDS Biotechnology‘s patent involves vaccine compositions with cationic lipids and antigens to induce immune responses in mammals. The method includes administering the vaccine to achieve enhanced CD 8+ T cell response. GlobalData’s report on PDS Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on PDS Biotechnology, Recombinant viral vaccines was a key innovation area identified from patents. PDS Biotechnology's grant share as of April 2024 was 30%. Grant share is based on the ratio of number of grants to total number of patents.
Vaccine composition with cationic lipid for immune response enhancement
A recently granted patent (Publication Number: US11911465B2) discloses a method for inducing both a humoral immune response and a CD 8+ T cell response in mammals by administering a vaccine composition containing a lipid and a multi-epitope viral antigen. The lipid in the composition is a cationic lipid, specifically R-DOTAP, which enhances the CD 8+ T-cell response by at least 2-fold compared to the viral antigen alone. The humoral immune response triggered by the vaccine is primarily an antibody response, making it a promising approach for enhancing immune responses in mammals, particularly humans.
Furthermore, the patent details the use of a modified influenza antigen within the vaccine composition to increase the hydrophobicity of the antigen, thereby improving its efficacy in inducing antigen cross-presentation. The method also includes the bonding of the modified protein or peptide to a hydrophobic group, such as a palmitoyl group, with a linker sequence. This innovative approach aims to enhance the CD 8+ T cell response significantly, making it a potential candidate for a universal influenza vaccine. Additionally, the patent covers the application of this method for treating diseases in mammals by administering the vaccine composition to induce both humoral and CD 8+ T cell responses, with the CD 8+ T-cell response being enhanced by at least 2-fold compared to using the viral antigen alone. This method holds promise for improving immune responses and potentially advancing the development of effective vaccines for various diseases.
To know more about GlobalData’s detailed insights on PDS Biotechnology, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
